EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：81

作者：

Ke, E-E ^{[1
,2
]}

Wu, Yi-Long ^{[1
,2
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期

关键词：

GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;

D O I：

10.1016/j.tips.2016.09.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.

引用

页码：887 / 903

页数：17

共 119 条

[91] Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer [J].

Song, Haa-Na ;

Jung, Ki Sun ;

Yoo, Kwai Han ;

Cho, Jinhyun ;

Lee, Ji Yun ;

Lim, Sung Hee ;

Kim, Hae Su ;

Sun, Jong-Mu ;

Lee, Se-Hoon ;

Ahn, Jin Seok ;

Park, Keunchil ;

Choi, Yoon-La ;

Park, Woongyang ;

Ahn, Myung-Ju .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :E45-E47

[92]

Soo R, 2015, ANN ONCOL, V26, P143

[93] Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902 [J].

Sugawara, S. ;

Oizumi, S. ;

Minato, K. ;

Harada, T. ;

Inoue, A. ;

Fujita, Y. ;

Maemondo, M. ;

Yoshizawa, H. ;

Ito, K. ;

Gemma, A. ;

Nishitsuji, M. ;

Harada, M. ;

Isobe, H. ;

Kinoshita, I. ;

Morita, S. ;

Kobayashi, K. ;

Hagiwara, K. ;

Kurihara, M. ;

Nukiwa, T. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :888-894

[94] Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses [J].

Sundaresan, Tilak K. ;

Sequist, Lecia V. ;

Heymach, John V. ;

Riely, Gregory J. ;

Jaenne, Pasi A. ;

Koch, Walter H. ;

Sullivan, James P. ;

Fox, Douglas B. ;

Maher, Robert ;

Muzikansky, Alona ;

Webb, Andrew ;

Tran, Hai T. ;

Giri, Uma ;

Fleisher, Martin ;

Yu, Helena A. ;

Wei, Wen ;

Johnson, Bruce E. ;

Barber, Thomas A. ;

Walsh, John R. ;

Engelman, Jeffrey A. ;

Stott, Shannon L. ;

Kapur, Ravi ;

Maheswaran, Shyamala ;

Toner, Mehmet ;

Haber, Daniel A. .

CLINICAL CANCER RESEARCH, 2016, 22 (05) :1103-1110

[95] Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas [J].

Taniguchi, Kazuya ;

Uchida, Junji ;

Nishino, Kazumi ;

Kumagai, Toru ;

Okuyama, Takako ;

Okami, Jiro ;

Higashiyama, Masahiko ;

Kodama, Ken ;

Imamura, Fumio ;

Kato, Kikuya .

CLINICAL CANCER RESEARCH, 2011, 17 (24) :7808-7815

[96] EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291 [J].

Thress, Kenneth S. ;

Brant, Roz ;

Carr, T. Hedley ;

Dearden, Simon ;

Jenkins, Suzanne ;

Brown, Helen ;

Hammett, Tracey ;

Cantarini, Mireille ;

Barrett, J. Carl .

LUNG CANCER, 2015, 90 (03) :509-515

[97] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M [J].

Thress, Kenneth S. ;

Paweletz, Cloud P. ;

Felip, Enriqueta ;

Cho, Byoung Chul ;

Stetsonl, Daniel ;

Dougherty, Brian ;

Lai, Zhongwu ;

Markovets, Aleksandra ;

Vivancos, Ana ;

Kuang, Yanan ;

Ercan, Dalia ;

Matthews, Sarah E. ;

Cantarini, Mireille ;

Barrett, J. Carl ;

Jaenne, Pasi A. ;

Oxnard, Geoffrey R. .

NATURE MEDICINE, 2015, 21 (06) :560-562

[98] Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies [J].

van Cruijsen, H ;

Giaccone, G ;

Hoekman, K .

INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (06) :883-888

[99] Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC [J].

Walter, Annette O. ;

Sjin, Robert Tjin Tham ;

Haringsma, Henry J. ;

Ohashi, Kadoaki ;

Sun, Jing ;

Lee, Kwangho ;

Dubrovskiy, Aleksandr ;

Labenski, Matthew ;

Zhu, Zhendong ;

Wang, Zhigang ;

Sheets, Michael ;

St Martin, Thia ;

Karp, Russell ;

van Kalken, Dan ;

Chaturvedi, Prasoon ;

Niu, Deqiang ;

Nacht, Mariana ;

Petter, Russell C. ;

Westlin, William ;

Lin, Kevin ;

Jaw-Tsai, Sarah ;

Raponi, Mitch ;

Van Dyke, Terry ;

Etter, Jeff ;

Weaver, Zoe ;

Pao, William ;

Singh, Juswinder ;

Simmons, Andrew D. ;

Harding, Thomas C. ;

Allen, Andrew .

CANCER DISCOVERY, 2013, 3 (12) :1404-1415

[100] Differentially expressed microRNAs in the serum of cervical squamous cell carcinoma patients before and after surgery [J].

Wang, Wen-Tao ;

Zhao, Ya-Nan ;

Yan, Jin-Xing ;

Weng, Mei-Ying ;

Wang, Yan ;

Chen, Yue-Qin ;

Hong, Shun-Jia .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7

← 3 4 5 6 7 8 9 10 11 12 →